Search - tctmd.com

Displaying 1 - 20 of 40

Sort: Relevancy | Date

News Industry News

The Lancet Publishes Twelve-Month Results for DESSOLVE III Highlighting MiStent® Performance in All-Comers Randomized Trial

December 06, 2017

News Opinion Editor's Corner TCT 2017

My Takeaways From TCT 2017: Show Up, Keep It Civil, and Bring Your Best Self

Shelley Wood

November 22, 2017

Presentation TCT 2017

ABSORB II 4-Year, ABSORB III 3-Year, ABSORB IV 30-Day: Appreciation and Critique

Presenter: Martin B. Leon, Marco Valgimigli, Giulio G. Stefanini

November 01, 2017

Presentation TCT 2017

ABSORB II 4-Year, ABSORB III 3-Year, ABSORB IV 30-Day: Highlights Summary

Presenter: Martin B. Leon, Marco Valgimigli, Gregg W. Stone

November 01, 2017

Presentation TCT 2017

Bioresorbable Scaffolds and Stents: From PROSPECT-ABSORB to PREVENT (With Case Examples)

Presenter: Gregg W. Stone, Peter H. Stone, Jung-Min Ahn

November 01, 2017

Presentation TCT 2017

Do Some, All, or None of the Outcomes With the First Generation Absorb Scaffold Imply a Class Effect for All BRS? Educated Insights

Presenter: Bernard R. Chevalier, Corrado Tamburino, Yoshinobu Onuma

October 31, 2017

Presentation TCT 2017

TCT 14: Safety and Clinical Performance of the Drug-Eluting Absorbable Metal Scaffold in the Treatment of Subjects With De Novo Lesions in Native Coronary Arteries at 12-Month Follow-up - BIOSOLVE-II and BIOSOLVE-III

Presenter: Stephan Achenbach, Jacques J. Koolen, Ron Waksman

October 31, 2017

Presentation TCT 2017

ABSORB PSP: Impact of Technique on Early and Late Outcomes Following Coronary Bioresorbable Scaffold Implantation

Presenter: Y. S. Chandrashekhar, David J. Moliterno, Gregg W. Stone

October 31, 2017

News Conference News TCT 2017

Long-term Absorb BVS Data Continue to Disappoint

Michael O'Riordan

October 31, 2017

News Conference News TCT 2017

Live From Denver: TCT 2017, Day Two

Shelley Wood

October 31, 2017

Presentation TCT 2017

ABSORB III: 3-Year Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease

Presenter: Patrick W. Serruys, Stephen G. Ellis

October 31, 2017

Presentation TCT 2017

How to Interpret Noninferiority Trials (eg, ABSORB III, EVEREST II, and Others)

Presenter: Roxana Mehran, Robert W. Yeh, Sanjay Kaul

October 30, 2017

Presentation TCT 2017

Drug Eluting Scaffold With an Absorbable Platform for Primary Lower Extremity Arterial Revascularization DESappear Study Initial Results

Presenter: Tony Das, Thomas Zeller

October 30, 2017

Presentation TCT 2017

Predicting The Future: Will the ABSORB III/IV Ten-Year Results Change How We Currently View Bioresorbable Vascular Scaffolds?

Presenter: C. Michael Gibson, Stephan Windecker, Stephan Achenbach

October 30, 2017

News Opinion Fellow Talk

My Picks for Fellows Attending TCT 2017

Amit K. Gupta, MBBS, MD

October 26, 2017

News Conference News TCT 2017

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

Shelley Wood

October 20, 2017

News Daily News

Absorb BVS Again Linked to Scaffold Thrombosis at 1 Year and Beyond

Michael O'Riordan

October 17, 2017

News Features

Absorb Vanishes, but Can Other Bioresorbable Scaffolds Make Magic Happen?

Michael O'Riordan

September 13, 2017

News Daily News

Boston Scientific Scraps Biodegradable Scaffold Program

Michael O'Riordan

August 01, 2017

News Daily News

New Absorb BVS Meta-analysis Begs the Question: When to Stop Studying a First-Gen Device?

Shelley Wood

July 21, 2017

Advertisement

The Lancet Publishes Twelve-Month Results for DESSOLVE III Highlighting MiStent® Performance in All-Comers Randomized Trial

My Takeaways From TCT 2017: Show Up, Keep It Civil, and Bring Your Best Self

ABSORB II 4-Year, ABSORB III 3-Year, ABSORB IV 30-Day: Appreciation and Critique

ABSORB II 4-Year, ABSORB III 3-Year, ABSORB IV 30-Day: Highlights Summary

Bioresorbable Scaffolds and Stents: From PROSPECT-ABSORB to PREVENT (With Case Examples)

Do Some, All, or None of the Outcomes With the First Generation Absorb Scaffold Imply a Class Effect for All BRS? Educated Insights

TCT 14: Safety and Clinical Performance of the Drug-Eluting Absorbable Metal Scaffold in the Treatment of Subjects With De Novo Lesions in Native Coronary Arteries at 12-Month Follow-up - BIOSOLVE-II and BIOSOLVE-III

ABSORB PSP: Impact of Technique on Early and Late Outcomes Following Coronary Bioresorbable Scaffold Implantation

Long-term Absorb BVS Data Continue to Disappoint

Live From Denver: TCT 2017, Day Two

ABSORB III: 3-Year Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease

How to Interpret Noninferiority Trials (eg, ABSORB III, EVEREST II, and Others)

Drug Eluting Scaffold With an Absorbable Platform for Primary Lower Extremity Arterial Revascularization DESappear Study Initial Results

Predicting The Future: Will the ABSORB III/IV Ten-Year Results Change How We Currently View Bioresorbable Vascular Scaffolds?

My Picks for Fellows Attending TCT 2017

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

Absorb BVS Again Linked to Scaffold Thrombosis at 1 Year and Beyond

Absorb Vanishes, but Can Other Bioresorbable Scaffolds Make Magic Happen?

Boston Scientific Scraps Biodegradable Scaffold Program

New Absorb BVS Meta-analysis Begs the Question: When to Stop Studying a First-Gen Device?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content